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Clinical Issues in Animal Models of Stroke and Rehabilitation
Steven C. Cramer
S troke remains the third greatest killer in the UnitedStates. Patients surviving a stroke often have signifi-cant impairment and disability. During the weeks to
months after a stroke, most patients show some improve-
ment in clinical status, but the extent of recovery is often
insufficient. As a result, stroke remains the leading cause of
adult disability in the United States (Gresham et al. 1995)
Since the 1970s, an increased number of clinical trials
have focused on new therapies for acute stroke (Uchino et
al. 2001). Although in many cases animal models have
shown efficacy in improving outcome, very few human tri-
als have documented clinical benefit, and the benefit has
generally been in relation to hyperacute thrombolysis. A
number of authors have explored the basis for these out-
comes of clinical trials in acute stroke (del Zoppo 1995;
Fisher and Ratan 2003; Grotta 1995; RCTEAST 2001), and
future trials will likely take advantage of these lessons.
Thus, development of new therapeutic options is still
needed for a common and devastating medical condition.
This need is compounded by the fact that nationally, more
than 98% of patients with acute stroke are not accessing
currently approved hyperacute thrombolytic options (Reed
et al. 2001). Many of the articles in this issue of ILAR
Journal describe new approaches for understanding and im-
proving outcome after stroke. In this context, several clini-
cal issues are worth emphasizing.
Patients with acute stroke are heterogeneous. Premorbid
neurological function is variable, multiple stroke risk fac-
tors and concomitant diseases are often present, the site of
the lesions is very variable, and the average age in the
United States is approximately 71 yr with high variance. A
number of pathophysiological processes can produce an
acute stroke, such as low flow, embolism, or hemorrhage.
However, many animal studies introduce experimental in-
farcts into only one location (mostly cortical) into homoge-
neous, young, healthy animals in an identical way.
Increased attention to clinical heterogeneity in preclinical
studies may yield results that more consistently extrapolate
to the human condition.
In many stroke studies—experimental animal and hu-
man—the time period between early intervention (typically
hours to days after stroke) and assessment of primary out-
come (usually 3 mo after stroke) is a physiological black
box. Additional behavioral measures may be tabulated dur-
ing this interim, but often little more is measured or even
considered. However, the events during this period of res-
toration may have substantial impact on final outcome. For
example, a distinct pharmacology characterizes the events
of this clinical period (Gladstone and Black 2000). In ex-
perimental animal studies, specific chemical insults intro-
duced during this period worsen neurological status; the
limited data available on this topic in humans are concor-
dant but inconclusive (Feeney et al. 1982; Goldstein 1998;
Lazar et al. 2002). Further studies are needed to increase our
understanding of this phenomenon.
The pharmacology of recovery may also be an avenue
for improving outcome after stroke. Several new therapeutic
approaches are described herein. Growth factors, cellular
therapies, catechol-related compounds, and other small mol-
ecules have been found to improve behavioral outcome in
experimental animal stroke models, often with a time win-
dow measured in days to weeks. Pilot human studies are
promising thus far. Human brain mapping studies are be-
ginning to yield data on the physiology of recovery that may
soon prove useful for guiding restorative treatment proto-
cols (Cramer et al. 2002; Green et al. 1999; Marshall et al.
2000; Nelles et al. 1999; Traversa et al. 1997). More re-
cently, animal models have been introduced that allow non-
invasive brain mapping of the events related to recovery
after stroke (Dijkhuizen et al. 2003).
The role of physiotherapy in clinical practice is becom-
ing more firmly established. Studies using animal models
have described benefit from increased motor activity after
experimental infarct (Jones et al. 1999; Nudo et al. 1996).
Evidence in human studies increasingly suggests that high
levels of physiotherapy after stroke may be associated with
improved clinical outcome (Kwakkel et al. 1999), although
it remains unclear whether one school of therapeutic ap-
proach is of greater or lesser efficacy than the others.
Increased environmental complexity has been shown in
normal animals and in animal models of stroke to affect
brain and behavior favorably (Johansson and Belichenko
2002; Kempermann et al. 1997; Kolb and Gibb 1991). How-
ever, there has been limited translation of this work into the
human experience.
A range of other clinical considerations commonly af-
fect recovery after stroke in human patients but are not
commonly addressed in animal models. The clinical course
after stroke in humans commonly includes a number of
complications. A majority of human patients are diagnosed
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with complications such as deep venous thrombosis, pul-
monary embolism, aspiration pneumonia, urinary tract in-
fection, or cardiac ischemia during the course of recovery
from stroke (Dromerick and Reding 1994; Kalra et al.
1995). Careful medical therapy during the poststroke reha-
bilitation phase can reduce the incidence of these events and
thereby support behavioral recovery. These clinical accom-
paniments are not usually incorporated into animal models
of stroke and stroke recovery. Cognitive deficits after stroke
are common and often devastating. Recent work with ani-
mal models has begun to address some of these issues, as
described herein. Depression is present in 30 to 40% of
stroke patients, and its presence may correlate with poorer
outcome (Paolucci et al. 2001). Increased attention in ani-
mal models to measures that correspond to depression might
increase the generalization of results to stroke recovery in
humans. From a broader perspective, the animal behaviors
used to assess whether a new treatment improves outcome
after experimental infarct sometimes have only an indirect
or limited relationship with clinical endpoints of interest to
human patients.
Clearly, it will be necessary to address a large number of
issues to understand the complex changes that take place in
the central nervous system after stroke and to devise means
to offer treatments for stroke survivors with permanent dis-
ability. The strongest bridges between animal models and
the human condition after an acute stroke may be built on
consideration of numerous social, physical, psychiatric,
pharmacological, and medical morbidity issues. The recent
development of additional animal models of stroke and the
more recent increased focus on recovery models have re-
sulted in substantial progress toward these ends. The articles
contained within this issue are part of a body of research
that will pave the way to a new set of tools to promote
poststroke recovery.
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